Kezar Life Sciences appoints Jain IR as Vice President of External Affairs
SAN FRANCISCO: Kezar Life Sciences, a biotechnology company developing treatments for patients with autoimmune diseases and cancers, has hired Gitanjali Jain as vice president of investor relations and external affairs.
Jain will lead Kezar’s investor relations, public relations and science communications efforts, the company said on Wednesday.
Jain previously worked as an MD at Solebury Trout, an investor relations and corporate communications firm, where she advised more than 50 biopharmaceutical companies on corporate strategy, investor relations, communications and capital market transactions.
“We are delighted to welcome Gita to the team as we continue to work to provide new therapies for patients living with difficult conditions,” John Fowler, co-founder and CEO of Kezar, said in a statement. “Gita’s strong investor relationships and proven track record of success in the industry will add tremendous value to Kezar, and I look forward to working in partnership with her.
Kezar, who is based in San Francisco, is developing a therapy, KZR-616 that “has the potential to be an important new treatment for patients with autoimmune diseases”, such as lupus nephritis, and a therapy, KZR-261, which acts as a “broad spectrum anti-tumor agent,” according to the company’s website.
“I am delighted to join Kezar at a pivotal time for the company as we continue to advance KZR-616, our first immunoproteasome inhibitor and KZR-261, our first protein secretion inhibitor,” said Jain in a statement. “I am honored to be able to contribute to the team and to Kezar’s future growth as we work to create therapies that address areas of significant unmet need for patients. “
In addition to Solebury Trout, Jain worked in a lab as a research associate at biopharmaceutical companies Medarex and StemCells.